Welcome to our dedicated page for BOUNDLESS BIO news (Ticker: BOLD), a resource for investors and traders seeking the latest updates and insights on BOUNDLESS BIO stock.
Boundless Bio, Inc. (Nasdaq: BOLD) is a clinical-stage oncology company whose news flow centers on the development of ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers. Company press releases highlight progress in its Phase 1/2 POTENTIATE trial, which evaluates the oral CHK1 inhibitor BBI-355 and, more recently, a combination arm pairing BBI-355 with the oral RNR inhibitor BBI-825 in patients with oncogene-amplified tumors.
Investors following BOLD news can expect regular updates on clinical development milestones, including enrollment status, portfolio prioritization decisions, and the evolution of Boundless Bio’s therapeutic strategy. The company has reported decisions to discontinue certain BBI-355 monotherapy and combination arms, while prioritizing a novel combination of BBI-355 and BBI-825 based on preclinical evidence of synergistic anti-tumor activity and a dosing approach that seeks to avoid overlapping toxicity.
News releases also cover the advancement of BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader targeting ecDNA segregation and inheritance. Boundless Bio communicates its plans for IND-enabling studies and anticipated IND submission timelines for BBI-940, along with broader pipeline activities supported by its Spyglass platform. In addition, the company issues quarterly and annual financial results and provides commentary on its cash runway and operational priorities, framed as forward-looking statements subject to risks described in its SEC filings.
Another recurring theme in BOLD news is conference participation and scientific presentations. Boundless Bio announces appearances at healthcare investor conferences and oncology meetings, such as the Goldman Sachs Global Healthcare Conference, the Needham Virtual Healthcare Conference, the Piper Sandler Annual Healthcare Conference, and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. These events often feature fireside chats or poster presentations on BBI-355, BBI-825, and the BBI-940 kinesin program.
For readers tracking BOLD, this news page aggregates company-issued updates on clinical trials, ecDTx pipeline progress, financial reporting, and investor and scientific conference activity related to Boundless Bio’s focus on extrachromosomal DNA (ecDNA) biology.
Boundless Bio (Nasdaq: BOLD) announced FDA acceptance of its IND for BBI-940, a novel Kinesin oral degrader, enabling a first-in-human trial (KOMODO-1) in metastatic breast cancer expected to start in the first half of 2026. The company reported preclinical anti-tumor activity including single-agent tumor regressions in xenograft models and said it expects initial proof-of-concept clinical data within its cash runway. Following portfolio prioritization, Boundless has ceased enrollment in the Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825) and said the revised plan extends its operating runway into the second half of 2028.
Boundless Bio (Nasdaq: BOLD) announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:30 a.m. ET in New York, NY.
A live and archived webcast will be available in the Events & Presentations section of Boundless Bio's Investors website.
Boundless Bio (Nasdaq: BOLD) reported third quarter 2025 results and program updates on Nov 5, 2025. The company had $117.6 million in cash, cash equivalents, and short-term investments as of Sept 30, 2025, stated to support operations into the first half of 2028. Enrollment is ongoing in the BBI-355/BBI-825 combination arm of the Phase 1/2 POTENTIATE trial. An IND submission for BBI-940 is on track and a first-in-human Phase 1 trial is expected in the first half of 2026. Q3 2025 results: R&D $10.7M (Q3 2024: $14.1M), G&A $4.5M (Q3 2024: $4.6M), and net loss $13.9M (Q3 2024: $16.5M).
Boundless Bio (Nasdaq: BOLD) announced a poster presentation at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22–26, 2025 in Boston, MA. The poster, titled "Synergistic oral combination of selective RNR inhibitor BBI‑825 with selective CHK1 inhibitor BBI‑355 targets unique dependencies of oncogene amplified cancers", is Abstract Number LB‑A022 in Poster Session A.
The session is scheduled for Thursday, October 23, 2025, 12:30–4:00 PM ET at Level 2, Exhibit Hall D.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company, reported Q2 2025 financial results and business updates. The company has opened enrollment for the BBI-355/BBI-825 combination arm of the POTENTIATE trial, targeting oncogene amplified cancers. Additionally, their novel kinesin program candidate BBI-940 is progressing toward IND submission in H1 2026.
Financial highlights include a strong cash position of $127.1 million, supporting operations into H1 2028. Q2 2025 showed reduced net loss of $15.7 million compared to $17.0 million in Q2 2024, with R&D expenses at $12.2 million and G&A expenses at $4.8 million.
Rice Biotech Launch Pad has appointed Carolyn Ng, a business unit partner at TPG Life Sciences Innovations, to its external advisory board. Ng brings significant expertise in biotech and company building, with extensive experience guiding early to midstage companies across various therapeutic areas.
Currently leading investments at TPG Life Sciences Innovations in San Francisco, Ng serves on multiple boards including Mbrace Therapeutics, Adcendo Aps, and Bicara Therapeutics (NASDAQ: BCAX). Her appointment marks her as the 16th member of the Launch Pad's external advisory board, joining leaders from various prestigious institutions and companies.
The Rice Biotech Launch Pad, based in Houston, focuses on accelerating the translation of Rice University's health and medical technology discoveries into practical medical solutions.
Boundless Bio (NASDAQ: BOLD), a clinical-stage oncology company, reported its Q1 2025 financial results and business updates. The company ended Q1 with a strong cash position of $138.3 million, providing runway into 2027. Key highlights include:
The company anticipates initial proof-of-concept data from its BBI-355 Phase 1/2 POTENTIATE trial in oncogene-amplified cancers in H2 2025. Their novel Kinesin program is progressing, with development candidate nomination expected by mid-2025 and IND filing planned for H1 2026.
Financial results show R&D expenses of $12.1 million (down from $13.1M in Q1 2024), G&A expenses of $5.2 million (up from $3.8M), and a net loss of $15.8 million (compared to $15.4M). The company also presented promising preclinical data for BBI-825, showing potential in preventing resistance in colorectal cancer models when combined with RAS inhibitors.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, has announced its participation in the upcoming Needham Virtual Healthcare Conference.
The company's President and CEO, Zachary Hornby, will deliver a presentation on Thursday, April 10, 2025, at 1:30 p.m. ET. Investors and interested parties can access both the live and archived webcasts of the presentation through the 'Events & Presentations' section of Boundless Bio's website or directly via the provided webcast link.
FAQ
What is the current stock price of BOUNDLESS BIO (BOLD)?
What is the market cap of BOUNDLESS BIO (BOLD)?
